Plain-English Summary
STEP 1 is the flagship obesity trial showing that weekly semaglutide 2.4 mg produced large average weight loss over 68 weeks in adults without diabetes when paired with lifestyle intervention.
Key Findings
- Mean body weight changed by -14.9% with semaglutide versus -2.4% with placebo at week 68.
- A much larger share of participants reached clinically meaningful weight-loss thresholds with semaglutide, including at least 5% body-weight loss.
- Cardiometabolic risk markers, including waist circumference and blood pressure, generally moved more favorably with semaglutide than placebo.
- Gastrointestinal adverse events were common and were more frequent with semaglutide than placebo.
Limitations
- The trial excluded people with diabetes, so the findings should not be generalized to all metabolic-disease populations.
- Controlled trial conditions, lifestyle counseling, and follow-up intensity differ from broad real-world use.
- The trial shows strong 68-week efficacy, but does not answer indefinite treatment, discontinuation, affordability, or long-term adherence questions.
Why It Matters
This is one of the core studies behind semaglutide's weight-management story, but it should be read as a treated-trial-population result rather than a promise of effortless or permanent weight loss for every user.
Viral Vitalism Verdict
High-value human evidence for obesity treatment efficacy, with the usual GLP-1 caveats: side effects, adherence, cost, discontinuation, and patient selection still matter.
Sources
- Once-weekly semaglutide in adults with overweight or obesity - New England Journal of Medicine
- STEP 1 semaglutide obesity trial - PubMed